x
Filter:
Filters applied
- Research Letters
- Agi, JorgeRemove Agi, Jorge filter
Publication Date
Please choose a date range between 2020 and 2020.
Research Letters
1 Results
- Research Letter
Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab
Canadian Journal of OphthalmologyVol. 56Issue 1p66–70Published online: September 10, 2020- Rona Z. Silkiss
- Michael K. Paap
- Kelsey A. Roelofs
- Jorge Agi
- Ezekiel Weis
Cited in Scopus: 8Within the last decade, novel biologics have emerged as a promising treatment for thyroid eye disease (TED), both as primary therapy and as an alternative to methotrexate or radiation in patients with steroid-refractory disease. Upregulation of several cytokines, including interleukin-6 (IL-6), have been implicated in the pathogenesis of TED.1 Tocilizumab (RoActemra, Hoffman-La Roche, Basel, Switzerland) is a recombinant humanized monoclonal antibody inhibitor of the IL-6 receptor. Its off-label intravenous use has been previously described in 2 case reports and a randomized trial to demonstrate clinical improvement in corticosteroid-resistant TED.
